WebDec 10, 2007 · This study demonstrates that intensified VCB has a high response rate (86% CR) with low toxicity and no engraftment failures. The 5-year PFS and OS rates of 62 and 57% are similar to other CBV... WebFeb 2, 2024 · Objective To determine the response, toxicity, and survival outcomes in lymphoma patients who underwent ASCT with CBV (cyclophosphamide, carmustine, and …

Impact of LEAM and CBV conditioning on gastrointestinal toxicity …

Webfamiliarity and experience with a particular regimen. Objective To determine the response, toxicity, and survival outcomes in lymphoma patients who underwent ASCT with CBV … fields biloxi

Outcome of CBV (Carmustine, Cyclophosphamide, …

WebJul 26, 2004 · Reece DE, Nevill TJ, Sayegh A et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin ... WebFeb 13, 2015 · Multivariate analysis showed that in comparison to BEAM, the risk of IPS for each regimen was as follows: CBV low, hazard ratio (HR), 1.07 (95% CI, .72 to 1.60); P = .742; CBV high, HR, 1.88 (95% CI, 1.24 to 2.83); P = .003; BuCy, HR, 1.25 (95% CI, .82 to 1.92); P = .30; and TBI, HR, 2.03 (95% CI, 1.30 to 3.19); P = .002 ( Table 2 ). WebCBV regimen: 600 mg/m 2 as a single dose 3 days prior to transplant (in combination with cyclophosphamide and etoposide) ... Dosing adjustment for toxicity: The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in ... grey twin bed with drawers